%D8%AA%D9%86%D8%AA%D8%B1%D8%AC_%D8%A7%D9%84%D8%AF%D9%85%D0%90%D0%B7%D0%B0%D1%82%D1%8D%D0%BC%D1%96%D1%8FAzot%C3%A4mieAzotemiaAzotemiaAzotemijaAzotemiaAzotemia%E9%AB%98%E5%B0%BF%E7%B4%A0%E7%AA%92%E7%B4%A0%E8%A1%80%E7%97%87AzotemieAzotemia%D0%90%D0%B7%D0%BE%D1%82%D0%B5%D0%BC%D0%B8%D1%8FAzotemija%D0%90%D0%B7%D0%BE%D1%82%D0%B5%D0%BC%D0%B8%D1%98%D0%B0Azotemi%D0%90%D0%B7%D0%BE%D1%82%D0%B5%D0%BC%D1%96%D1%8FQ794072
about
TTP and aHUS in Complicated PregnanciesErythropoietin in Hemolytic Uremic SyndromeOutcame of Cases With Hemolytic Uremic Syndrome Attending Assiut University Child HospitalEculizumab to Treat Thrombotic Microangiopathy/Atypical Hemolytic Uremic Syndrome -Associated Multiple Organ Dysfunction Syndrome in Hematopoietic Stem Cell Transplant RecipientsAtypical Hemolytic-Uremic Syndrome (aHUS) RegistryaHUS Observational Long Term Follow-UpEculizumab Use in the Postpartum Period for the Treatment of Pregnancy Associated aHUS: A Case SeriesOutbreak of Hemolytic Uremic Syndrome Linked to Escherichia Coli of Serotype O104:H4A Study of an Investigational Drug, Cemdisiran (ALN-CC5), in Patients With Atypical Hemolytic Uremic SyndromeA Retrospective, Observational, Non-interventional Trial to Assess Eculizumab Treatment Effect in Patients With Atypical Hemolytic Uremic Syndrome (aHUS)Haemolytic Uraemic Syndrome in Childhood: Clinical, Cognitive and Psychological AspectsThe Safety and Efficacy of Eculizumab in Japanese Patients With Atypical Hemolytic Uremic Syndrome (aHUS)To Characterize the Safety and Tolerability of Eculizumab in Two Japanese aHUS PatientsAn Open-Label, Multi-Center Clinical Trial of Eculizumab in Pediatric Patients With Atypical Hemolytic-Uremic SyndromeComplement Activation During Hemodialysis in Atypical Hemolytic Uraemic Syndrome as Underlying Kidney DiseaseAn Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With Atypical Hemolytic-uremic SyndromeOpen Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Resistant aHUSOpen Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-Resistant aHUSOpen Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Sensitive aHUSOpen Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-sensitive Atypical Hemolytic Uremic Syndrome (aHUS)Sensitivity and Specificity of NGAL in an Emergency Room PopulationShiga Toxin Producing Escherichia Coli (STEC) Volume ExpansionStudy Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With aHUSComplement Inhibition in aHUS Dialysis PatientsAzithromycin in Post Diarrheal Haemolytic and Uremic SyndromeRituximab in Patients With Relapsed or Refractory TTP-HUSSafety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic SyndromeStudy of ALXN1210 in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS)Phase III Randomized Study of SYNSORB Pk in Children With E. Coli-Associated Hemolytic Uremic SyndromeSingle Arm Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Patients With Atypical Hemolytic Uremic Syndrome (aHUS)Study of 'Vascular Competence' Profile and Endothelial Activation in the Hemolytic Uremic Syndrome in Children and AdultsThe Role of Microparticles as a BiomarkerEculizumab in Shiga-toxin Related Hemolytic and Uremic Syndrome Pediatric Patients - ECULISHU
P1050
P780
The cardiac biomarker NT-proBNP is increased in dogs with azotemia.Comparison of the diagnostic value of symmetric dimethylarginine, cystatin C, and creatinine for detection of decreased glomerular filtration rate in dogsThe association of indoxyl sulfate with fibroblast growth factor-23 in cats with chronic kidney diseaseChanges in thyroid and renal function after bilateral thyroidectomy in cats
P921
Q61907296-6D7C643B-CD89-4AD7-9818-E1C774E6DB6AQ62030789-35966663-F75E-424E-A2C3-AB93831B08C8Q62054199-78480B56-4474-4A6B-BEBA-AF811FA64977Q62817228-136AE695-3EB5-4B57-9909-BBB71D337EA2Q63319884-1024635D-E10C-45C5-B167-24F098D8EF7BQ63319887-BAF97795-6489-410E-9949-A17A62C2914AQ63396967-CE6E4B49-DAEA-4182-BE37-8D8F11F01BF9Q63806806-6A463D8F-6449-40B1-A546-FDF7E33A875BQ63811565-27C30088-1C5B-470C-8A29-55AC2AE193E2Q63836470-7E7F8770-9A05-4C2C-A9B9-97D4311E2745Q63837426-757FC1DD-38F1-4AD1-908A-1D8BEA50B678Q63838036-ABD1077C-D755-4EAA-8293-213E69EF77E0Q63838769-3C31437F-4B0B-4B90-B67E-1E03F4D7DF28Q64652372-50AFE5B1-E46C-4F04-B041-C4D364A5CEDAQ64673745-662CAE4D-784D-4579-BFA0-C541EDD3ECC0Q64678132-7813B240-3885-4A0A-9731-9B5BA98440A9Q64681091-F1213114-B834-4DDE-9E0D-26129950DFD7Q64681129-F0D9F69E-EE61-43B9-B4D8-5F22D11F57CBQ64681138-610EB9B2-93BD-4262-BFEB-821ED94E38F8Q64694331-B7BEB675-3E1C-4CD9-BC15-CC6EF125A523Q64710246-4C4D7487-DD5A-4D6A-94AB-B05AD4505AB9Q64819142-D500963F-6E5B-48B3-9204-D899EC9AEA0DQ65317682-729A3603-B2FE-4710-A687-6DDE53B2266BQ65346310-95053282-8ACD-4E75-904E-5CA77B7198E6Q65350112-BAD25A24-AFA5-481D-BD2D-4005E7A30BEAQ65472581-613305F2-9033-435F-ADB9-9607956A6E93Q66041489-B633DC83-3237-443B-A78B-64FD1920BF2AQ66044465-0EAAF6B3-2511-40C7-A73D-EEF92526157CQ66061902-7567B51D-B414-4DFC-B55D-076B1EE9BC76Q66078864-AC3DA193-2BDE-44C5-B65C-5DE29D27FBD1Q66082221-C0127182-0940-41AE-B8DB-F7797D1C407BQ66411150-BBFC5617-E54A-428A-8293-8704B21F437BQ67134835-DF31FB48-BA7E-4A45-A47B-B058118307B6
P1050
description
Krankheit
@de
Odolean produktu nitrogenatu g ...... asun hepatikoaren seinale dena
@eu
Parametro di laboratorio
@it
abnormally high levels of nitrogen in the blood
@en
condición clínica caracterizada por niveles anormalmente altos de compuestos nitrogenados
@es
name
Azotemia
@es
Azotemia
@id
Azotemie
@nl
Azotemija
@hr
Azotemija
@sh
Azotämie
@de
azotemi
@sv
azotemia
@en
azotemia
@it
azotemia
@pt
type
label
Azotemia
@es
Azotemia
@id
Azotemie
@nl
Azotemija
@hr
Azotemija
@sh
Azotämie
@de
azotemi
@sv
azotemia
@en
azotemia
@it
azotemia
@pt
altLabel
Azoemia
@es
أزوتيمية
@ar
prefLabel
Azotemia
@es
Azotemia
@id
Azotemie
@nl
Azotemija
@hr
Azotemija
@sh
Azotämie
@de
azotemi
@sv
azotemia
@en
azotemia
@it
azotemia
@pt
P672
P486
P508
P6366
P646
P2888
P2892
P2924
P31
P3219
P3471
P3827
P3841
HP:0002157
P4746
P486
P6366
2775919214
P646
P672
C12.777.419.936.231
C13.351.968.419.936.231
C23.550.145